Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 49 - Preparations for testing in vivo
Patents for A61K 49 - Preparations for testing in vivo (35,376)
03/2003
03/27/2003US20030059426 Method for inducing selectively suppressed immune response to transplanted tissue or cells
03/27/2003US20030059400 Comprises DNA sequence encoding a detectable, cytotoxic protein or protein capable of inducing a detectable signal (luminescent or fluorescent); tumor imaging; gene expression
03/27/2003US20030059373 Contrast agents
03/27/2003US20030059372 Of a biocompatible polymer, a biocompatible solvent and a biocompatible contrast agent; for treating vascular lesions via catheter delivery
03/27/2003US20030059371 Compositions injectable via a catheter to form occlusive masses in a selected body region; highly dispersed in a liquid medium of given specific gravity; nonclumping in the delivery equipment during embolization
03/27/2003DE10137512C1 Gleitschutzvorrichtung für Fahrzeugräder Anti-skid device for vehicle wheels
03/27/2003CA2460808A1 Immune response associated proteins
03/27/2003CA2459140A1 Protein modification and maintenance molecules
03/27/2003CA2459022A1 Neurotransmission-associated proteins
03/26/2003EP1294949A2 Human tumor necrosis factor delta and epsilon
03/26/2003EP1294769A1 Antibodies that immunospecifically bind to blys
03/26/2003EP1294758A2 Regulation of human substance p-like g protein-coupled receptor
03/26/2003EP1294726A2 Improvements in and relating to chromophores
03/26/2003EP1294409A2 Membrane-permeant peptide complexes for medical imaging
03/26/2003EP1294408A1 Rhodamine diagnostic agent and diagnostic methods for detection of epithelial cancer
03/26/2003EP1294274A2 Optical imaging of induced signals in vivo under ambient light conditions
03/26/2003EP1294227A2 Transgenic mice containing nuclear hormone receptor gene disruptions
03/26/2003EP1007105B1 Method for producing contrast agents largely free of side-effects
03/26/2003EP1007102B1 Process for preparing contrast agents
03/26/2003EP0847240B1 Novel embolizing compositions
03/26/2003EP0835138B1 Preparation for diagnostic of the metabolic syndrome and diseases including the syndrome
03/26/2003EP0740528B1 Gas microspheres for topical and subcutaneous application
03/26/2003CN1404878A Novel lipide supersonic contrast medium and preparation method thereof
03/26/2003CN1103606C Bi papcitide-based pharmaceutical compositions for imaging and treating thrombi
03/26/2003CN1103605C Administrable compositions and method for magnetic resonance imaging
03/26/2003CN1103604C Iron-containing nano particles with double coating and their use in diagnosis and therapy
03/26/2003CN1103588C Calcium complex of 4-(4-ethoxybenzyl)-3,6,9-tris (carboxylatomethyl)-3,6,9-triazaundecanedioic acid and its salt, pharmaceutical agents containing these complexes
03/25/2003US6538174 Animal model for transplantation
03/25/2003US6537825 Hyperpolarized noble gas extraction methods, masking methods, and associated transport containers
03/25/2003US6537814 Compositions and methods for altering the biodistribution of biological agents
03/25/2003US6537579 Compositions and methods for administration of pharmacologically active compounds
03/25/2003US6537533 Hair conditioner composition that is non-irritating to the eyes
03/25/2003US6537521 Chelate compounds; magnetic resonance imaging contrast agent
03/25/2003US6537520 Diagnosis and treatment of cancer; kit containing compound having peptide or peptidomimetic functionality that binds to a alpha v beta 3 receptor linked to a chelator
03/25/2003US6537246 Oxygen delivery agents and uses for the same
03/25/2003CA2224093C Human vascular endothelial growth factor 2
03/25/2003CA2177492C Preparation of hollow microcapsules
03/20/2003WO2003023432A1 A method of using spectral-spatial exitation at magnetic resonance imaging
03/20/2003WO2003023404A1 A method of diagnosis and treatment and agents useful for same
03/20/2003WO2003023341A2 Thermographic metthod
03/20/2003WO2003022308A2 Therapeutic insert and therapeutic method
03/20/2003WO2003022265A1 Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
03/20/2003WO2003022264A1 Paclitaxel mixed composition and water-in-oil type emulsion formulation for chemoembolization and preparation method thereof
03/20/2003WO2003022248A1 Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
03/20/2003WO2003022042A1 Enhanced resolution of tumor metastasis
03/20/2003WO2003004466A3 Dye-sulfenates for dual phototherapy
03/20/2003WO2002096366A3 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
03/20/2003WO2002087424A3 Treatment and diagnosis of macrophage mediated disease
03/20/2003WO2002069908A3 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
03/20/2003WO2002018620A3 Neutrokine-alpha and neutrokine-alpha splice variant
03/20/2003WO2001085219A3 Identification, diagnosis, and treatment of breast cancer
03/20/2003US20030056239 NMP35 apoptosis inhibitor gene disruptions, compositions and methods related thereto
03/20/2003US20030056233 Induction of psoriasis in animal model; obtain cells, transfer to transgenic rodent, administer cytokine, monitor development of skin disorder
03/20/2003US20030055386 Threaded syringe with quick stop
03/20/2003US20030055341 Detection of cancer using cellular autofluorescence
03/20/2003US20030055307 Devices for detection and therapy of atheromatous plaque
03/20/2003US20030054439 Truncated soluble tumor necrosis factor type-I and type-II receptors
03/20/2003US20030054045 Formulations for therapeutic agents absorbed through mucous membranes
03/20/2003US20030054027 Charged lipids and uses for the same
03/20/2003US20030054003 Antitumor agents, anticarcinogenic agents
03/20/2003US20030053954 Magnetic resonance imaging agents for the detection of physiological agents
03/20/2003US20030053953 Wherein void comprises vapor of volatile liquid (aliphatic hydrocarbons, chlorofluorocarbons, tetraalkyl silanes, and perfluorocarbons); for computed tomography imaging of the gastrointestinal region
03/20/2003US20030053951 Use of non-invasive imaging technologies to monitor in vivo gene-expression
03/20/2003US20030053949 Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
03/20/2003US20030052305 Thermochromic liquid crystalline medium encapsulated in a light transmissive polymeric material, useful in decorative applications, cosmetics, thermodiagnostic and security applications
03/20/2003CA2460092A1 A method of diagnosis and treatment and agents useful for same
03/20/2003CA2460049A1 Enhanced resolution of tumor metastasis
03/20/2003CA2456726A1 A method of using spectral-spatial exitation at magnetic resonance imaging
03/19/2003EP1292684A2 Proteases
03/19/2003EP1292675A2 Method of diagnosing, monitoring, staging, imaging and treating colon cancer
03/19/2003EP1292613A2 Chimeric gfp-aequorin as bioluminescent ca?++ reporters at the single cell level
03/19/2003EP1292359A2 System and method for assessing the performance of a pharmaceutical agent delivery system
03/19/2003EP1292298A1 Intracorporeal medicaments for high energy phototherapeutic treatment of disease
03/19/2003EP0952853B1 Conjugate comprising an active agent, a polypeptide and a polyether
03/19/2003EP0890066B1 Cryogenic accumulator for spin-polarized xenon-129
03/19/2003EP0682530B1 Gas mixtures useful as ultrasound contrast media
03/19/2003CN1403160A Color gastrointestinal ultrasonic contrast medium
03/18/2003US6534041 Acid-labile and enzymatically divisible dye compounds for diagnosis with near infrared light and for therapy
03/18/2003US6534040 Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
03/18/2003US6534039 Extended organic cobalt and nickel magnetic complexes
03/18/2003US6534035 Methods of inhibiting clot formation
03/18/2003CA2107107C Improvements in or relating to contrast agents
03/18/2003CA2059432C Surface modified drug nanoparticles
03/13/2003WO2003020949A2 Targeted nucleic acid constructs and uses related thereto
03/13/2003WO2003020751A2 Homing peptides
03/13/2003WO2003020701A2 Multi-use multimodal imaging chelates
03/13/2003WO2003020323A1 Light-stabilized $i(in vivo) stain composition and method of manufacture
03/13/2003WO2003020320A2 Nanoparticles comprising biologically active tnf which is immobilised on the same
03/13/2003WO2003020262A2 Use of polyunsaturated fatty acids for intra-arterial injection for selectively occluding blood supplies to neoplasias
03/13/2003WO2002088666A3 Method for identifying lymph nodes
03/13/2003WO2002082972A3 Method and apparatus to optimize drug therapy
03/13/2003WO2002081653A3 An animal model for enteric pathogens
03/13/2003WO2002058739A3 Orally ingestible baked radiopaque product for testing for dysphagia
03/13/2003US20030049721 Glycoconjugates and methods
03/13/2003US20030049617 Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes
03/13/2003US20030049262 Methods for identification, diagnosis, and treatment of breast cancer
03/13/2003US20030049203 Targeted nucleic acid constructs and uses related thereto
03/13/2003US20030049158 Stablization and terminal sterilization of phospholipid formulations
03/13/2003US20030047083 Method and apparatus for magnetic resonance imaging of arteries using a magnetic resonance contrast agent
03/13/2003CA2459796A1 Homing peptides
1 ... 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 ... 354